Lack of Consistent Associations Between Pharmacologic Gastric Acid Suppression and Adverse Outcomes in Patients With Coronavirus Disease 2019: Meta-Analysis of Observational Studies-Reference-Cited by-同舟云学术

Lack of Consistent Associations Between Pharmacologic Gastric Acid Suppression and Adverse Outcomes in Patients With Coronavirus Disease 2019: Meta-Analysis of Observational Studies

Published:2021-06 Issue:7 Volume:160 Page:2588-2590.e7
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Kamal Faisal,Khan Muhammad Ali,Sharma Sachit,Imam Zaid,Howden Colin W.

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference17 articles.

1. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series

2. Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study

3. Association Between Famotidine Use and COVID-19 Severity in Hong Kong: A Territory-wide Study

4. Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match Study in 7158 Hospitalized Patients With Coronavirus Disease 2019 From a Large Healthcare System

5. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proton Pump Inhibitors and Risk of COVID-19 Infection in Children;The Journal of Pediatrics;2024-11

2. Continuous co-prescription of rebamipide prevents upper gastrointestinal bleeding in NSAID use for orthopaedic conditions: A nested case-control study using the LIFE Study database;PLOS ONE;2024-06-11

3. Effect of famotidine on cognitive and behavioral dysfunctions induced in post-COVID-19 infection: A randomized, double-blind, and placebo-controlled study;Journal of Psychosomatic Research;2023-09

4. Antacids in real clinical practice;Meditsinskiy sovet = Medical Council;2023-05-19

5. Drugs in primary care that may alter COVID-19 risk and severity;JAAPA;2023-05